Integral Molecular wins COVID-19 NIAID award

By The Science Advisory Board staff writers

April 23, 2020 -- The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Integral Molecular $1 million to help discover vaccines and therapeutics to combat the novel coronavirus.

Integral Molecular will use its Shotgun Mutagenesis Epitope Mapping platform to identify the best antibody candidates to help develop an improved COVID-19 vaccine. The company will also utilize its Membrane Proteome Array platform to identify proteins that allow the novel coronavirus to invade cells. The system has been deployed on other epidemics, including the Zika, Ebola, and Chikungunya viruses.

If you like this content, please share it with a colleague!

Related Reading

NIAID announces new COVID-19 priorities
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) has released a new strategic plan for accelerating research to diagnose, prevent,...

NIH tests for SARS-CoV-2 antibodies in the general population
The U.S. National Institutes of Health (NIH) has commenced a study to determine how many adults in the U.S. with no confirmed history of infection with...

Better flu treatments on the way thanks to the discovery of broadly protective antibodies
Research from the National Institutes of Allergy and Infectious Diseases (NIAID) isolated the antibodies from a person sick with the flu five days after...

NIH Invests $100 million in cures for sickle cell disease and HIV
The National Institutes of Health (HIH) announced that it plans to invest at least $100 million over the next four years towards developing affordable,...